|
Article summaries 2011 - 2012 |
- |
|
|
|
Scientific Articles
Most of the presented research article summaries were created by the EHDN
science writer Diana Raffelsbauer, on behalf of the EHDN Newsletter Editorial Board.
EHDN aims to inform the lay community and healthcare professionals about current efforts and progress towards finding a cure for Huntington’s disease.
|
Comprehensive behavioral
testing in the R6/2 mouse model
of Huntington’s disease shows no
benefit from CoQ10 or minocyclineLiliana B. Menalled et al. am01-jan2011-issue12-en A randomized, placebocontrolled
trial of latrepirdine
in Huntington‘s disease
Karl Kieburtz et al. am02-jan2011-issue12-en Cell loss in the motor and cingulate
cortex correlates with symptomatology
in Huntington’s diseaseDoris C. V. Thu et al. am03-jan2011-issue12-en Observing Huntington’s disease:
the European Huntington’s Disease
Network’s REGISTRY
Michael Orth and the European Huntington‘s Disease
Network am04-apr2011-issue13-en Biological and clinical changes
in premanifest and early stage
Huntington’s disease in the TRACKHD
study: the 12-month longitudinal
analysis
Sarah J. Tabrizi et al. am05-apr2011-issue13-en Matrix metalloproteinases
are modifiers
of huntingtin proteolysis
and toxicity in
Huntington’s disease
John P. Miller et al. am06-apr2011-issue13-en | | Early changes in
the hypothalamic
region in prodromal
Huntington
disease revealed
by MRI analysis
Charlotte Soneson et al. am08-jul2011-issue14-en An antisense CAG repeat transcript
at the JPH3 locus mediates
expanded polyglutamine protein
toxicity in Huntington‘s diseaselike
2 mice
Brian Wilburn et al. am09-jul2011-issue14-en Discrepancies in reporting
the CAG repeat lengths for
Huntington’s disease
Oliver Quarrell et al. am10-jan2012-issue15-en Functional gene expression
profiling in yeast implicates
translational dysfunction in
mutant huntingtin toxicity
Eran Tauber et al. am11-jan2012-issue15-en A natural antisense transcript at
the Huntington’s disease repeat
locus regulates HTT expression
Daniel W. Chung et al. am12-jan2012-issue15-en Pridopidine for the treatment of
motor function in patients with
Huntington’s disease (MermaiHD):
a phase 3, randomised, doubleblind,
placebo-controlled trial
Justo G. de Yébenes et al. am01-jan2012-issue15-en |
|